News
Curated oncology headlines from reputable sources, ranked by importance with Claude Opus 4.7.
Context-dependent synthetic lethality — an emerging precision therapeutic approach
A comprehensive review published in Nature Reviews Cancer by Chang et al. presents a framework for understanding context-dependent synthetic lethality, where specific genetic backgrounds in tumors create exploitable vulnerabilities. The authors evaluate how various genetic contexts produce cancer-intrinsic weaknesses that can be targeted therapeutically. The framework specifically considers therap…
Enhancer and metabolic rewiring by KMT2C–COMPASS or KMT2D–COMPASS family loss in cancer creates druggable vulnerabilities
A new review published in Nature Reviews Cancer examines how loss-of-function mutations in the KMT2C or KMT2D components of the COMPASS chromatin-modifying complex drive cancer progression through enhancer and metabolic rewiring. The authors, Zhao and Shilatifard, systematically catalog the druggable vulnerabilities that emerge from altered COMPASS activity, spanning epigenetic, metabolic, immune,…
New payloads drive next-gen antibody–drug conjugates
A review published in Nature Cancer examines the emerging landscape of next-generation antibody–drug conjugate (ADC) payloads designed to overcome growing tumor resistance. As conventional ADC payloads face increasing efficacy challenges, researchers are exploring novel drug classes including immunotherapeutic agents, radioligands, and repurposed older compounds as alternative warheads. The articl…
Epithelial-to-mesenchymal transition as a central driver of tumor cell plasticity
A comprehensive review published in Nature Cancer by Jimenez-Castaño and Nieto examines the latest understanding of epithelial-to-mesenchymal transition (EMT) as a central mechanism driving tumor cell plasticity. The authors highlight how cancer cells exploit various EMT states to promote tumor progression, enable metastatic dissemination, and modulate responses to therapy. The review synthesizes …
Oncolytic viruses and cytokine-based gene therapies reprogram the tumor microenvironment
A comprehensive review published in Nature Cancer by Chiocca and colleagues examines how oncolytic viruses and cytokine-based gene therapies can reprogram the tumor immune microenvironment to enhance anti-cancer responses. The overview synthesizes current knowledge on how these biological agents alter immune cell composition, signaling pathways, and immunosuppressive barriers within tumors. Unders…
Tumor-localized CD40 agonism with MP0317, a FAP x CD40 DARPin, reprograms the tumor microenvironment in patients with advanced solid tumors: an open-label, nonrandomized, dose-escalation phase 1 study
Researchers led by Steeghs have published results from a first-in-human phase 1 dose-escalation trial of MP0317, a novel bispecific DARPin molecule that simultaneously targets fibroblast activation protein (FAP) on tumor stroma and the immune-stimulatory receptor CD40. The study demonstrated that tumor-localized CD40 agonism can reprogram the tumor microenvironment in patients with advanced solid …
Alliance A222001: Oxybutynin Versus Placebo for the Treatment of Hot Flashes in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer
A randomized, placebo-controlled trial (Alliance A222001) published in the Journal of Clinical Oncology evaluated oxybutynin, an anticholinergic agent, for the management of hot flashes in prostate cancer patients undergoing androgen-deprivation therapy (ADT). Hot flashes are among the most common and distressing side effects of ADT, significantly affecting quality of life for a large proportion o…
Nivolumab ± Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trial
Results from the randomized phase II NIPINEC trial (GCO-001), published in the Journal of Clinical Oncology, evaluated the efficacy of nivolumab alone versus nivolumab combined with ipilimumab in patients with previously treated advanced neuroendocrine carcinoma (NEC). Neuroendocrine carcinomas are rare, aggressive malignancies with very limited treatment options after progression on first-line pl…
Financial Hardship Before Diagnosis: Influence on Late-Stage Cancer Presentation and the Role of Screening
A study published in the Journal of Clinical Oncology examined how pre-diagnosis financial hardship influences the likelihood of patients presenting with late-stage cancer and whether screening programs can mitigate this effect. The researchers found that individuals experiencing significant financial difficulties before a cancer diagnosis were more likely to be diagnosed at advanced stages, when …
The Oncology Care Model and Payments, Utilization, and Quality
A study published in JAMA evaluated the Medicare Oncology Care Model (OCM), a major alternative payment program designed to improve the value of cancer care delivered to Medicare beneficiaries. Using a difference-in-differences regression design, researchers compared Medicare spending, healthcare utilization, and quality-of-care metrics between oncology practices that voluntarily participated in t…